Growth Hormone Axis
Top 5 Growth Hormone Research Peptides
CJC-1295 · Ipamorelin · IGF-1 LR3 · Sermorelin · Tesamorelin
Comprehensive research guide to the five most studied growth hormone peptides. From extended-release GHRH analogues to selective ghrelin receptor agonists, explore the complete somatotropic axis research toolkit used by leading research institutions worldwide.
CJC-1295 Research Applications
Long-acting GHRH analogue with DAC technology enabling extended release for sustained somatotropic axis research.
Long-Term GH Studies
- Chronic growth hormone elevation research
- Age-related GH decline investigations
- Sleep architecture and GH pulsatility studies
- Metabolic syndrome research protocols
- Protein synthesis and muscle preservation studies
DAC Technology Mechanism
The Drug Affinity Complex creates reversible bonds with albumin, acting as a natural depot system that slowly releases active CJC-1295 over several days, providing sustained GHRH receptor stimulation without frequent administration.
Pharmacokinetic Research
- Extended half-life mechanism studies
- Albumin binding kinetics research
- Bioavailability enhancement protocols
- Dose-response optimization studies
- Comparative pharmacology with native GHRH
- Metabolite identification and tracking
Clinical Research Models
- Growth hormone deficiency studies
- Aging and hormone replacement research
- Injury recovery and tissue repair protocols
- Cognitive function and memory studies
- Cardiovascular health research
- Bone density and mineralization studies
Extended Release Studies
CJC-1295's sustained profile allows researchers to study chronic GH elevation effects without frequent dosing complications, providing cleaner data on long-term growth hormone effects.
IGF-1 Profiling
Consistent IGF-1 elevation across multi-week periods enables detailed biomarker tracking and dose-optimization studies with reliable, reproducible results.
Combination Research
Frequently combined with Ipamorelin to achieve synergistic pituitary stimulation through complementary GHRH and ghrelin receptor pathways.
Ipamorelin Research Studies
Highly selective growth hormone releasing peptide with superior tolerability and clean GH response profile.
Precision GH Research
- Isolated growth hormone effect studies
- Pediatric growth research applications
- Elderly population hormone studies
- Gender-specific GH response research
- Dose-response optimization protocols
- Long-term safety assessment studies
Selective Mechanism
Ipamorelin's high selectivity for ghrelin receptors ensures research data reflects pure GH-mediated effects without confounding variables from appetite or stress hormone changes — critical for clean experimental outcomes.
Mechanistic Studies
- Ghrelin receptor subtype research
- Post-receptor signaling pathway studies
- Receptor desensitization protocols
- Pituitary responsiveness research
- Growth hormone pulse amplitude studies
- Comparative secretagogue research
Clinical Applications
- Growth hormone deficiency diagnostics
- Muscle wasting research models
- Bone health and density studies
- Recovery and repair mechanism research
- Sleep quality and GH relationship studies
- Anti-aging research protocols
Selective Research Tool
Ipamorelin's selectivity profile makes it ideal when researchers need pure GH release data unconfounded by changes in other hormonal axes.
Population Research
Excellent tolerability allows for research across diverse populations — from pediatric to geriatric subjects — with minimal adverse effect concerns.
Combination Synergy
When co-administered with CJC-1295, produces synergistic GH release by stimulating complementary receptor pathways simultaneously.
IGF-1 LR3 Research Applications
Long-acting recombinant IGF-1 analogue for direct downstream growth hormone axis research.
Muscle Research
- Satellite cell activation and proliferation
- Muscle protein synthesis pathway studies
- Muscle fiber type differentiation research
- Exercise adaptation mechanism studies
- Muscle wasting prevention protocols
- Hypertrophy vs. hyperplasia research
Enhanced Muscle Effects
IGF-1 LR3 directly activates IGF-1 receptors in peripheral tissues without requiring hepatic processing, enabling tissue-specific anabolic effects crucial for muscle, bone, and neural repair research.
Neurological Research
- Neuroprotective mechanism studies
- Neurogenesis and brain development research
- Cognitive function enhancement studies
- Neurodegenerative disease models
- Spinal cord injury recovery research
- Brain aging and plasticity studies
Cellular Research
- Cell proliferation and survival studies
- Apoptosis prevention research
- Stem cell differentiation protocols
- Tissue repair and regeneration studies
- Metabolic pathway activation research
- Receptor signaling mechanism studies
Anabolic Research
IGF-1 LR3 bypasses pituitary control, allowing isolated study of peripheral IGF-1 effects on muscle hypertrophy, protein synthesis, and satellite cell activation.
Neural Applications
CNS IGF-1 receptor expression makes this compound valuable for neuroprotection and neurogenesis research in aging and neurodegenerative disease models.
Direct Cellular Action
Bypasses the pituitary axis to directly activate IGF-1 receptors, enabling clean studies of downstream anabolic signaling pathways.
Sermorelin Research Studies
The reference standard GHRH fragment for physiological growth hormone axis stimulation research.
Diagnostic Research
- Growth hormone deficiency testing protocols
- Pituitary function assessment studies
- Age-related GH decline research
- Stimulation test optimization
- Reference standard establishment
- Comparative diagnostic method studies
Diagnostic Gold Standard
Sermorelin's well-established pharmacology and predictable response patterns make it the reference standard for GH stimulation testing, providing reliable baseline data for comparing novel secretagogues.
Physiological Studies
- Natural GH pulsatility research
- Hypothalamic-pituitary axis studies
- Circadian rhythm and sleep research
- Stress response mechanism studies
- Feedback regulation research
- Hormone interaction studies
Population Studies
- Pediatric growth research
- Geriatric somatopause research
- Gender-specific GH response studies
- Long-term safety profiling
- Cross-population comparative research
Reference Standard
Sermorelin's predictable pharmacokinetics make it the gold standard reference for comparing novel growth hormone secretagogues and stimulation protocols.
Circadian Research
Bedtime administration aligns with natural nocturnal GH release patterns, enabling circadian rhythm and sleep architecture studies with physiological relevance.
Ageing Models
Sermorelin response tracks functional pituitary somatotroph reserve, making it a sensitive marker for age-related somatopause research.
Tesamorelin Research Applications
Trans-3-hexenoic acid modified GHRH analogue with unique visceral adiposity research profile.
Visceral Fat Research
- Visceral adipose tissue reduction studies
- Regional fat distribution mechanisms
- Cardiovascular risk factor studies
- Inflammatory marker research
- Adipokine regulation studies
- Metabolic syndrome research protocols
Unique Research Value
Tesamorelin's specific efficacy profile provides researchers with a unique tool to study the mechanisms by which GH affects regional fat distribution — particularly valuable in HIV-associated lipodystrophy and metabolic disorder research.
Mechanism Studies
- GH-mediated lipolysis research
- Adipocyte biology and function studies
- Growth hormone receptor research
- IGF-1 pathway activation studies
- Lipid metabolism research
- Hormone-sensitive lipase studies
Metabolic Syndrome
Tesamorelin's visceral fat reduction profile makes it valuable for metabolic syndrome research, studying relationships between visceral adiposity and cardiometabolic risk.
Lipodystrophy Models
Well-established in HIV-associated lipodystrophy research, providing a validated model for studying GH-mediated regional fat redistribution mechanisms.
Cognitive Research
GH-axis restoration through Tesamorelin enables study of hippocampal IGF-1 upregulation and its relationship to cognitive function in metabolic disease models.
Growth Hormone Research Protocols
Standardized research protocols for each growth hormone peptide with best practice guidelines for study design.
CJC-1295 Protocol
- Administer 2–3 times weekly via subcutaneous injection
- Standard research dose: 1–2 mg per administration
- Monitor IGF-1 levels weekly for dose optimization
- Assess GH peaks 2–6 hours post-injection
- Include 4-week washout for receptor recovery
- Document injection site rotation and tolerance
- Control for circadian timing of administration
Ipamorelin Protocol
- Administer 1–3 times daily on empty stomach
- Research dose range: 200–300 mcg per injection
- Time doses 30 minutes before meals
- Monitor GH levels 15–30 minutes post-dose
- Assess for appetite and sleep effects
- Include washout periods to prevent tolerance
- Document any injection site reactions
IGF-1 LR3 Protocol
- Administer daily via subcutaneous or intramuscular route
- Research dose: 50–100 mcg per injection
- Monitor blood glucose levels closely
- Assess IGF-1 levels and IGFBP ratios
- Include muscle protein synthesis markers
- Control for exercise and nutrition timing
- Document local and systemic effects
Sermorelin Protocol
- Administer 1–3 times daily, preferably at bedtime
- Standard dose: 200–500 mcg per injection
- Monitor GH response 30–60 minutes post-dose
- Assess sleep quality and duration
- Include baseline and follow-up IGF-1 measurements
- Document natural GH pulsatility patterns
- Control for stress and exercise factors
Tesamorelin Protocol
- Administer daily via subcutaneous injection
- Research dose: 2 mg daily for visceral fat studies
- Monitor body composition via DEXA or MRI
- Assess metabolic markers (glucose, lipids)
- Include inflammatory biomarker analysis
- Document injection site reactions and tolerance
- Control for diet and exercise interventions
General Safety Guidelines
- Screen subjects for contraindications and allergies
- Monitor vital signs and general health status
- Include emergency protocols for adverse events
- Document all side effects and tolerability
- Maintain proper cold chain storage (2–8°C)
- Validate peptide purity and potency before use
- Follow institutional research ethics guidelines
| Parameter | CJC-1295 | Ipamorelin | IGF-1 LR3 | Sermorelin | Tesamorelin |
|---|---|---|---|---|---|
| Mechanism | GHRH-R agonist | GHS-R1a agonist | IGF-1R agonist | GHRH-R agonist | GHRH-R agonist |
| Half-life | 6–8 days | ~2 hours | ~13 hours | ~12 minutes | ~26 minutes |
| Dosing Frequency | 2–3×/week | 1–3×/day | Daily | 1–3×/day | Daily |
| Primary Research | Sustained GH elevation | Selective GH pulse | Muscle/neural | GH axis diagnostics | Visceral fat |
| Key Advantage | Extended release | High selectivity | Direct IGF-1R | Reference standard | Fat specificity |
Exclusive Research Applications Only
All growth hormone peptides described are intended strictly for scientific research purposes. These compounds are not approved for human therapeutic use. Researchers must follow all applicable institutional guidelines, ethical protocols, and regulatory requirements when conducting studies.